AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1573044
Drug: buspirone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone (20 mg)
Trial: 1573044
Drug: buspirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone (10 mg)
Trial: 6353523
Drug: secobarbital (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secobarbital (100 mg)
Trial: 3889230
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy with methotrexate and leucovorin followed by regional therapy and additional methotrexate courses every three months for one year.
Trial: 3889230
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with a combination of Adriamycin and cisplatin every three weeks for four cycles after the first 35 patients.
Trial: 27194493
Drug: TXA IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA IV and IA group (1 g IV preoperatively and 3 g IA postoperatively)
Trial: 27194493
Drug: TXA IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA IV and placebo group (1 g IV preoperatively and 100 mL saline IA)
Trial: 24915800
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg.kg(‐1) loading dose followed by 0.5 μg.kg(‐1).h(‐1) infusion)
Trial: 24915800
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% (bolus and infusion of equivalent volume)
Trial: 14651279
Drug: Dental-bonding agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dental-bonding agent (Solist) followed by resin composite (Ecusit)
Trial: 16921044
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus tamoxifen
Trial: 8687150
Drug: Tamoxifen or
RxNorm normalized name: tamoxifen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen or chemotherapy plus tamoxifen
Trial: 6441224
Drug: Cefonicid 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefonicid 1.0 g
Trial: 6441224
Drug: Penicillin 4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin 4.8 X 10(6) units plus 1.0 g of probenecid
Trial: 30616462
Drug: Gastric H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric H. pylori treatment plus periodontal therapy
Trial: 30616462
Drug: Gastric H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric H. pylori treatment alone
Trial: 29489568
Drug: Early Physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Physical Therapy (PT) for 3 weeks
Trial: 22311995
Drug: Child-targeted intervention
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child-targeted intervention (massage and humor therapy)
Trial: 17657948
Drug: Antihomotoxic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihomotoxic therapy
Trial: 11914565
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of crystalloid solution for preloading (Group A)
Trial: 11914565
Drug: 15 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml/kg of crystalloid solution for preloading (Group B)
Trial: 10023505
Drug: Fluoxetine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n = 10)
Trial: 2260153
Drug: Nimodipine 120
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine 120 mg orally
Trial: 31191790
Drug: Intermittent pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent pneumatic compression along with conventional treatment
Trial: 31191790
Drug: Cold-pack treatment
RxNorm normalized name: COLD PACK,INSTANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-pack treatment along with conventional treatment
Trial: 29257757
Drug: Formulation containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation containing buradae sandal safaid, safoofe maghze tukhme bakayin, safoofe khaste tamar hindi and safoofe shakkar safaid, 10 g B.D for 21 days
Trial: 29257757
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azithromycin, fluconazole and secnidazole, single dose
Trial: 11915783
Drug: HIGH carbohydrate
RxNorm normalized name: High carbohydrate food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH carbohydrate diet (greater than 70% of daily energy intake from CHO)
Trial: 11915783
Drug: LOW carbohydrate
RxNorm normalized name: Low carbohydrate beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW carbohydrate diet (less than 10% of daily energy intake from CHO)
Trial: 2577393
Drug: Clindamycin (q.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (q.i.d. 300 mg)
Trial: 2577393
Drug: Cephradine (q.i.d.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine (q.i.d. 250 mg)
Trial: 22372918
Drug: Standard community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard community care (CC) including nurse home visitation
Trial: 21825006
Drug: Olaparib in
RxNorm normalized name: Product containing olaparib in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib in combination with fractionated radiotherapy
Trial: 21825006
Drug: Olaparib alone
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib alone or in combination with fractionated radiotherapy
Trial: 15544709
Drug: Topical vapocoolant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vapocoolant Fluori‐Methane (FM)
Trial: 11764063
Drug: Interapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interapy treatment (experimental condition)
Trial: 9338731
Drug: Terazosin (alpha1-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin (alpha1-adrenergic antagonist)
Trial: 8239013
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 50 micrograms.kg‐1.min‐1
Trial: 8239013
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 75 micrograms.kg‐1.min‐1
Trial: 8239013
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 100 micrograms.kg‐1.min‐1
Trial: 8239013
Drug: Initial bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial bolus of propofol (2 mg.kg‐1)
Trial: 8239013
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion (all doses)
Trial: 3300953
Drug: Chemotherapy (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (six cycles of vincristine, doxorubicin, and cyclophosphamide)
Trial: 3300953
Drug: Levamisole immunotherapy
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole immunotherapy (150 mg/day, on 2 consecutive days weekly)
Trial: 26120010
Drug: Ethinyl estradiol/norgestimate
RxNorm normalized name: ETHINYL ESTRADIOL/NORGESTIMATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl estradiol/norgestimate (0.035/0.25 mg once daily)
Trial: 20106825
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine (CsA)
Trial: 20106825
Drug: Low-dose tacrolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tacrolimus (Tac)
Trial: 20106825
Drug: Low-dose sirolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sirolimus (SRL)
Trial: 20106825
Drug: Standard-dose cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cyclosporine (CsA)
Trial: 20106825
Drug: Standard-dose cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cyclosporine without induction
Trial: 17651705
Drug: High-dose olanzapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose olanzapine (up to 30 mg/day)
Trial: 17651705
Drug: Clozapine and
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine and High-dose olanzapine
Trial: 15653968
Drug: High-flow transtracheal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow transtracheal insufflation of oxygen-enriched air at 15 L/min (fraction of inspired oxygen, 0.37)
Trial: 15653968
Drug: Low-flow transtracheal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-flow transtracheal insufflation of oxygen at 1.5 L/min
Trial: 10841003
Drug: Prediction rule
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction rule based on sulfonylurea Rx, insulin Rx, duration of diabetes, and fasting glucose levels
Trial: 9347199
Drug: Ethanol infusion
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol infusion alone
Trial: 29851090
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) in addition to conventional therapy (compression garments, massage therapy, exercise) for 6 weeks; treatment details: wavelength 980/810 nm (80:20 ratio), output power 500 mW, beam spot size 5 cm2, irradiance 100 mW/cm2, treatment time per area 1 minute, total dosage delivered 300 J.
Trial: 29851090
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy alone (compression garments, massage therapy, exercise).
Trial: 9188997
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg midazolam
Trial: 9188997
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg midazolam
Trial: 20863007
Drug: Test FDC
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test FDC (rabeprazole 20 mg and diclofenac sodium 100 mg)
Trial: 20863007
Drug: Reference FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference FDC (rabeprazole 20 mg and diclofenac sodium 100 mg)
Trial: 15745762
Drug: Brimonidine tartrate
RxNorm normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brimonidine tartrate 0.2% (twice daily)
Trial: 15745762
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate 0.5% (twice daily)
Trial: 11054909
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and thienopyridines (specific dosages and duration not mentioned)
Trial: 11054909
Drug: Newer and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newer and more potent antiplatelet agents (specific agents not mentioned)
Trial: 11054909
Drug: Optimization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimization of antiplatelet therapy with aspirin and thienopyridines
Trial: 8842505
Drug: Nanterinone 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanterinone 2 mg
Trial: 30497837
Drug: 6 µg
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 µg hemagglutinin per strain (FluArt, Hungary)
Trial: 30497837
Drug: 15 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 µg hemagglutinin per strain (currently licensed vaccine)
Trial: 15023611
Drug: 500 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/d vitamin C
Trial: 15023611
Drug: 1000 mg/d
RxNorm normalized name: RibaTab 1000 MG/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/d grape-seed polyphenols
Trial: 1491345
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of moxisylyte (two formulations)
Trial: 3085257
Drug: Nebulised sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised sodium cromoglycate (single high dose)
Trial: 30234925
Drug: short‐infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: short‐infusion
Trial: 26470783
Drug: Exenatide (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (7.5 μg)
Trial: 23383459
Drug: Acupuncture group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture group (scalp acupoint Dingnie Qianxiexian (MS 6) and body acupoints Neiguan (PC 6), Jianyu (LI 15), Sanyinjiao (SP 6), treated once daily for 20 days)
Trial: 23383459
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine neurological therapies only)
Trial: 20190281
Drug: VIA-2291 (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIA-2291 (25, 50, or 100 mg daily for 12 weeks)
Trial: 10822428
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg L-dopa every 24 hours
Trial: 10822428
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg L-dopa every 8 hours
Trial: 10822428
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg L-dopa every 8 hours
Trial: 10822428
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg L-dopa every 24 hours (3 months prolonged treatment)
Trial: 10822428
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg L-dopa every 8 hours (3 months prolonged treatment)
Trial: 24139977
Drug: Adapted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted cognitive behaviour therapy (CBT-HA group)
Trial: 24139977
Drug: Adapted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted cognitive behaviour therapy (CBT-HA group) and Standard care
Trial: 23759035
Drug: Guided online
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided online sleep training based on Cognitive Behavioral Therapy for insomnia.
Trial: 17127828
Drug: Lamivudine at
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine at 100 mg/daily orally for 52 weeks
Trial: 17127828
Drug: Lamivudine at
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine at 100 mg/die plus alpha-interferon at 6 MU subcutaneously three times weekly for 52 weeks
Trial: 17127828
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (lamivudine plus alpha-interferon) for 40 weeks after pre-treatment with lamivudine for 12 weeks
Trial: 11908357
Drug: Colgate Winterfresh
RxNorm normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Winterfresh Gel (0.243% sodium fluoride in a silica base)
Trial: 8999672
Drug: Russian hepatitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Russian hepatitis B Combiotech vaccine (20 mg)
Trial: 8999672
Drug: Recombivax‐HB vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombivax‐HB vaccine (10 mg)
Trial: 1443845
Drug: Oxymetazoline hydrochloride
RxNorm normalized name: Oxymetazoline Hydrochloride
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxymetazoline hydrochloride (two sprays, 15 minutes before therapy)
Trial: 1443845
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water (control group, two sprays, 15 minutes before therapy)
Trial: 27935660
Drug: 0.12% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% CHX mouthrinses (Group II) used twice a week for 4 months
Trial: 25971288
Drug: Lower-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose edoxaban (LDE)
Trial: 25971288
Drug: Higher-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose edoxaban (HDE)
Trial: 16689041
Drug: Pill counts
RxNorm normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pill counts for psychotropic medications
Trial: 16689041
Drug: Medication Management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Management Administration Assessment (MMAA) role-play
Trial: 15160510
Drug: Meropenem plus
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem plus amikacin (20 mg/kg every 8 h plus 15 mg/kg/d in 2 divided doses)
Trial: 15160510
Drug: Piperacillin-tazobactam plus
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam plus netilmicin (100 mg/4 mg/kg every 8 h plus 7 mg/kg every 24 h)
Trial: 9001768
Drug: Loteprednol etabonate
RxNorm normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loteprednol etabonate 0.5% ophthalmic suspension (LE), q.i.d. for 6 weeks
Trial: 8105785
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray (one week's treatment)
Trial: 8105785
Drug: Budesonide (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (two weeks' treatment)
Trial: 27566742
Drug: Deflazacort 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort 0.9 mg/kg/d
Trial: 27566742
Drug: Deflazacort 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deflazacort 1.2 mg/kg/d
Trial: 23925646
Drug: Intraperitoneal 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal 0.25% bupivacaine (100 mg)
Trial: 16870658
Drug: OrM3 0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OrM3 0.5, 2, 3 or 4 mg orally once daily
Trial: 16870658
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 36 mug by inhalation four times daily
Trial: 8851905
Drug: Glucose (18.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose (18.5% w/v solution)
Trial: 8851905
Drug: Maize syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maize syrup solids (18.5% w/v solution)
Trial: 8851905
Drug: Sucrose (18.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (18.5% w/v solution)
Trial: 1632399
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy (atenolol, dihydroergotamine, domperidone, cafedrine, elastic compression stockings)
Trial: 6760390
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of sobrerol for 14 days
Trial: 6760390
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g glyceringuaiacol per day for 14 days
Trial: 26813467
Drug: Prodigest® (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prodigest® (two capsules)
Trial: 18508296
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of peginterferon‐alpha‐2a (180 microg/week) and ribavirin (1000‐1200 mg/day)
Trial: 18508296
Drug: 48 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48 weeks of peginterferon‐alpha‐2a (180 microg/week) and ribavirin (1000‐1200 mg/day)
Trial: 9088894
Drug: 0.1 IE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 IE per kg body weight regular insulin (insulin induced hypoglycemia)
Trial: 9088894
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml 0.9% sodium chloride (placebo)
Trial: 9088894
Drug: 0.1 IE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 IE per kg body weight regular insulin plus glucose 10% (euglycemic hyperinsulinemic glucose clamp)
Trial: 8192109
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (HDD) for 48 hours followed by intermediate-dose dexamethasone (IDD)
Trial: 8192109
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (HDD) followed by no steroids with cranial radiotherapy